EirGenix Showcases Its Dual-Engine CDMO and Biosimilars Strategy at BIO International 2026

EirGenix Showcases Its Dual-Engine CDMO and Biosimilars Strategy at BIO International 2026

Highlights

• Showcased EirGenix’s dual-track strategy integrating biosimilars and commercial-scale CDMO services at BIO 2026.
• Highlighted a comprehensive HER2-positive breast cancer portfolio spanning trastuzumab, pertuzumab, subcutaneous formulations, and next-generation ADC biosimilars.
• Demonstrated an integrated biologics CDMO platform supporting clients from cell line development through commercial GMP manufacturing.
• Expanded global partnership opportunities amid biologics patent expirations and ongoing biopharma supply chain restructuring.
• Positioned EirGenix as a trusted partner accelerating global biologics development and commercialization

 

Read the full article | CDMO & CRO Activity US BIO 2026, 2026/06/29

EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026